Our Mission

Breakthrough cancer therapies:
directing the immune system to eliminate tumor cells.

 
 
 
  Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies. The company engineers and develops next-generation bispecific antibodies – TandAbs ® - that bind with high specificity and affinity to certain cancer cells and direct the most potent cells of the human immune defense arsenal, Natural Killer cells (NK-cells) or T-cells, to attack and kill these cancer cells.

Affimed’s lead development candidate AFM13 is an NK-cell TandAb. It targets CD30 malignancies, notably Hodgkin Lymphoma (HL) and directs NK-cells to eliminate tumor cells by specifically attaching to their CD16A receptor. Promising clinical results from a phase 1 safety study using this first-in-class approach have been obtained. Affimed’s second clinical stage candidate AFM11 is a T-cell TandAb. It targets CD19 malignancies, notably non-Hodgkin Lymphoma (NHL), and directs T-cells to destroy the cancer cells by specifically attaching to their CD3 receptor. The company has another T-cell TandAb product entering preclinical development that targets Epidermal Growth Factor Receptor variant III (EGFRvIII) and directs T-cells to destroy the tumor cells. All three products have been discovered in-house, and Affimed retains full rights to its internal pipeline.

Affimed generates its pipeline of product candidates from three proprietary next-generation antibody engineering technologies:

 
 
     
  NK-cell TandAbs – these are tetravalent, bifunctional proteins that recognize a specific biologic target and, utilizing their second functionality, bind with high affinity to CD16A on NK cells and thereby direct the NK-cell to eliminate the target cell.  
     
 
     
  T-cell TandAbs – these are tetravalent, bifunctional proteins that recognize a specific biologic target and utilizing their second functionality, bind with high affinity to CD3 on T-cells and thereby direct the T-cell to eliminate the target cell.  
     
 
     
  Trispecific Abs for dual targeting of tumor cells – these are trifunctional structures that can be designed to target two different targets/epitopes on the tumor cell and with the third functionality bind with high affinity to either T-cells or NK-cells.  
     
 
 
     
 
  Affimed Pipeline  
   
 
 
 
  Compound Disease Target Immune Cell Target Lead Indication Discovery Preclinical Phase 1 Phase 2 Phase 3  
  AFM13 CD30 CD16A / NK-cell Hodgkin Lymphoma            
  AFM11 CD19 CD3 / T-cell Non-Hodgkin Lymphoma            
  AFM21 EGFRvIII CD3 / T-cell Solid Tumors            
  TandAb Undisclosed Undisclosed Hematological Malignancy            
  Affimed Program Partnered Program
 
 
 
  Impressum Disclaimer   © 2014 Affimed